Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
10 p, 290.8 KB Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer / Peters, S. (Lausanne University Hospital) ; Camidge, D.R. (University of Colorado) ; Shaw, A.T. (Massachusetts General Hospital) ; Gadgeel, S. (University of Michigan) ; Ahn, J.S. (Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Kim, D.W. (Seoul National University Hospital) ; Ou, S.H.I. (School of Medicine) ; Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ; Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zeaiter, A. (F. Hoffmann–La Roche) ; Mitry, E. (F. Hoffmann–La Roche) ; Golding, S. (F. Hoffmann–La Roche) ; Balas, B. (F. Hoffmann–La Roche) ; Noe, J. (F. Hoffmann–La Roche) ; Morcos, P.N. (Roche Innovation Center) ; Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). [...]
2017 - 10.1056/NEJMoa1704795
New England Journal of Medicine, Vol. 377 Núm. 9 (31 2017) , p. 829-838  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.